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ABSTRACT
GABRIELLA HARTMAN: REGULATING NEURONAL GROWTH WITH
STRUCTURALLY DEFINED GLYCANS
(Under the direction of Dr. Nicole Ashpole)
Chondroitin sulfate proteoglycans (CSPGs) and keratan sulfate proteoglycans
(KSPGs) play an important role in neural development. Aggrecan, a CSPG, operates in
the neural extracellular matrix where it negatively regulates neurite outgrowth to prevent
aberrant process formation. Unfortunately, this aggrecan or CSPG-rich/KSPG-rich barrier
can also prevent neuronal regeneration, which contributes to the inability to repair brain
and spinal cord injuries. Removal of CSPGs and KSPGs has been shown to increase
neurite outgrowth. We extend these findings by testing the ability of structurally-defined
glycans to outcompete aggrecan and allow neurite outgrowth. Our overall goal is to
determine if there is a particular glycan structure which can overcome inhibitory CSPGs
and KSPGs without inhibiting neurite outgrowth themselves. We utilized primary
cultures of rat neurons and applied polydisperse-related mixtures of CSPGs, KSPGs and
newly-isolated, novel glycans in the absence and presence of aggrecan. Several of these
glycans successfully removed the aggrecan-induced blockade while not inhibiting neurite
outgrowth on their own. We are currently investigating the efficacy of these compounds
in concentration-response curves and are testing additional glycans with different
molecular weights and varying sulfation patterns to determine the structural requirements
for the glycans as modulators of neurite outgrowth. By investigating the impacts of these
glycans, we will increase the understanding of proteoglycan regulation of neural structure
and function, and potentially identify compounds which could be used to treat spinal cord
injuries.
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I. Background
When the body is injured, natural defenses begin to work to repair the damaged
tissue. Inflammation, white blood cells, and a multitude of other factors combine to repair
the damaged site. As with many tissues, a scar will form following injury (Beller, 2014).
Traumatic brain injury (TBI) or spinal cord injury (SCI) lead to the formation of specific
type of scar tissue called glial scars, which are comprised of complex molecular
interactions and are poorly understood. Glial cells, the principal cells responsible of the
formation of glial scars, are a group of essential cells within the nervous system that
respond to injury and provide structural and metabolic support. Glial cells include
astrocytes, oligodendrocytes, and microglia. Following a SCI, specialized astrocytes will
coordinate the healing process and form the glial scar along with connective tissue.
Previous studies have shown the importance of the response of glial cells to injury and
the implications for permanent damage as a result. The glial scar acts as a protective, yet
inhibitory barrier, preventing regeneration of the spinal cord, ultimately leading to
permanent effects like paralysis (Daniell, 2012). Though it was commonly thought before
that the glial scar was a mechanical barrier to neuronal regeneration, it is now understood
that the upregulation of certain molecules in the glial scar may allow for neuronal
regeneration (Daniell, 2012). Because both TBI and SCI result in axonal injury, it is
thought that identification of molecules or mechanisms that permit axonal repair through
the scar may have the potential to improve outcomes following these injuries (Harris,
2009).
A major factor contributing to the inhibition of neurite outgrowth and regeneration is
the upregulation of inhibitory chondroitin sulfate (CS) and keratan-sulfate (KS)
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proteoglycans (CS/KSPGs) following a traumatic injury. Proteoglycans are glycoproteins
that have glycosaminoglycans (GAGs) attached and are a key component in the
extracellular matrix (ECM). They comprise nearly 20% of the ECM and are known to
have a role in the progression of disease, cell proliferation, and nervous system
development (Djerbal, 2017). GAGs are highly anionic linear polymers composed of
disaccharide units of either uronic acid or galactose and a hexosamine (Pomin, 2012).
CSPGs contain a carbohydrate chain with alternating N-acetylgalactosamine (GalNAc)
and glucuronic acid (GlcA) units with varying sulfation patterns, whereas KSPGs are
poly-N-acetyllactosamine chains (Varki, 2017). Together, CS/KSPGs also have glycan
chains varying in size, number, and sulfation patterns which allow for vast diversity in
the effects of CS/KSPGs on neurite regeneration and rehabilitation. Proteoglycans can
affect neurite outgrowth through interactions of the core protein and the GAG chains.
These interactions regulate various physiological processes such as inflammation,
metastasis, development, regeneration, coagulation, cell adhesion, growth, and neuronal
regeneration (Pomin, 2012). Though both core protein and GAG chain interactions have
been shown to impact neuronal growth, the mechanism by which these affect neuronal
regeneration is not well understood (Beller, 2014). However, the regulation of neurite
outgrowth is thought to be receptor mediated mechanisms – likely through RTN4R,
RTN4RL1, PTPRF, etc. It is unclear whether the CS/KSPGs interact with the receptor
either directly or indirectly (Daniell, 2012). Regardless, upregulation of proteoglycans
following injury in the CNS is indicative of decreased neurite outgrowth and a
nonpermissive growth environment, providing an opportunity for the introduction of a
possible therapeutic intervention (Daniell, 2012).
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Although the mechanism of CS/KSPGs and its inhibitory effects on neuronal
plasticity is largely unexplored and not completely understood, there is evidence that
disruption of the CS/KSPG interactions will increase neurite outgrowth and regeneration.
Aggrecan from bovine cartilage (a CS/KSPG) sufficiently inhibits axon outgrowth in an
in vitro culture model, and this inhibitory effect is lost following digestion of the CS
GAG chain or by alterations of the core protein (Ohtake, 2015). When aggrecan binds to
hyaluronic (HA), an important component of articular cartilage, large negatively charged
aggregates are formed (Figure 1) (Holmes, 1988). The ability of aggrecan to form
aggregates of hyaluronan (HA) and other properties are attributed to its high content of
CS (Collin, 2017). But, since aggrecan contains little KS, it is likely that the ability of
CS/KSPGs to inhibit neurite regeneration is due to the proper spatial presentation of both
KS and CS.
There is considerable diversity in glycan structure found in nature and it is known that
sulfated glycans from marine life have the potential biotherapeutic functions in the
organisms that produce them and exogenously in other organisms (Pomin, 2014).
Sulfated fucans from sea urchin egg jelly express variability in structure and sulfation
patterns among species. This species-specific differentiation regulates fertilization by
inducing an acrosomal reaction with only compatible sperm. Thus, structural changes in
glycans of the sea urchin egg jelly may lead to speciation and evolutionary changes, as
changes in the glycan structure ultimately leads to incompatibility between sperm and
egg.
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N-linked Glycans

GAGs

Figure 1: Structure of Aggrecan. Source(s): Millipore Sigma, [Structural Proteins –
Aggrecan]. Retrieved from https://www.sigmaaldrich.com/life-science/metabolomics/
enzyme-explorer/learning-center/structural proteins/aggrecan.html.
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We sought to examine whether novel glycans isolated from these sources can
outcompete CS/KSPGs such as aggrecan and ultimately regulate neuronal growth. To do
this, unique glycans from Lytechinus variegatus (L. variegatus) and Echinometra
lucunter (E. lucunter) were investigated in their effect on neuronal growth and
competition with CS/KSPGs. Two glycans were extracted and tested from the egg jelly of
L. variegatus, LVP1 and LVP2, and one glycan was extracted from E. lucunter, along
with their low molecular weight derivatives. LVP1 is a high molecular polymer of [LFucp4(SO3-)-α(1-3)-L-Fucp2,4(SO3-)-α(1-3)-L-Fucp2(SO3-)-α(1-3)-L-Fucp2(SO3-)]n.
The presence of electrostatic repulsion of the sulfates in the linking disaccharide [-3)-αL-Fucp-2(OSO3)-(1–3)-α-L-Fucp-4(OSO3)-(1-] between the tetrasaccharides accounts
for the increased motion in the glycan structure (Queiroz, 2015). LVP2 is a high
molecular weight polymer composed of [L-Fucp4(SO3-)]n, while the glycan from E.
lucunter is composed of [L-Gal2(SO3-)]n. All native forms are close to 100 kDa. Low
molecular weight derivatives were acquired by hydrolysis of native glycans. Hydrolyzed
E. lucunter glycans (ELHD) are composed of 60% [→3)-a-galactose(2SO3-)-(1→]n and
40% [→3)- a-galactose-(1→]n, and hydrolyzed LVP2 (LVP2HD) are composed of 80%
[→3)- a-fucose(4SO3-)-(1→]n and 20% [→3)- a-fucose-(1→]n and 20% [→3)- afucose-(1→]n. Therefore, the low molecular weight derivatives contain essentially the
same structure as the native form, but with less sulfation.
CS, the core protein of CSPGs, is the most abundant GAG endogenously
produced in the central nervous system and consists of repeating disaccharide units of Dglucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc). Various positions of CS
may be sulfated, giving rise to different residues of CS. For example, sulfation of C-4 of
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GalNAc gives rise to CS-A, C-6 of GalNAc gives rise to CS-C, C-2 of GlcA and C-6 of
GalNAc gives rise to CS-D, and C-4 and C-6 of GalNAc gives rise to CS-E (Djerbal,
2017). The sulfation patterns are vital to consider when investigating the interactions
between glycans of CS/KSPGs and neurons (Queiroz, 2015). Thus, prior to testing the
functional effects of these glycans in our neuron cultures, our collaborators conducted
NMR analysis to verify sulfation patterns, thereby allowing us to determine structurefunction relationships. It was determined that the CS preparation was approximately 50%
non-sulfation and approximately 50% 6-sulfation, indicating our novel glycans primarily
featured CS-C.
Other factors that influence glycan interactions with target cells are glycan
dynamics and conformation; however, little information on this is known on the exact
size and shape required for regulating neurons. There is a vast amount of diversity in
glycan size, shape, and sulfation pattern observed in nature. We set out to assess the
conformations and sulfation patterns may be serve as important biological regulators
within the ECM. We hypothesize that specific sulfated glycans isolated from sea urchins
will outcompete aggrecan and allow neurite outgrowth and that disruption of CSPG
and/or KSPG signaling will promote axonal regeneration. We tested a variety of
mammalian and marine sulfated glycans with unique structures and examined their
impact on neurite outgrowth. As controls, chondroitin sulfate (CS), chondroitinase,
enoxaparin, and heparin were examined as studies have shown that enzymes such as
keratanase and chondroitinase, as well as low molecular weight glycans prove to
effectively inhibit CS/KSPGs are restore growth following a SCI (Barriett et al., 2006,
Kim et al., 2006). Examining the both protein-GAG interactions and sulfation patterns in
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our neuronal growth assays may provide insight on the molecular mechanisms underlying
the regulation of neurite growth and regeneration (Pomin, 2012). This comprehensive
study of novel glycans, proteoglycan regulation, and growth of neurite processes has the
potential to provide insight into the mechanism by which CS/KSPGs operate and be a
resource to support further studies aimed at treatment and rehabilitation following a TBI
or SCI.
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II. Methods
Animals
All animal procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Mississippi and performed in accordance with
their approved guidelines. Timed-pregnant Sprague Dawley rats were ordered from
Envigo and arrived into the UM animal care facility at 17 days postcoitum and were
temporarily housed with access to food (Teklad 7001) and water ad libitum until the time
of euthanasia (described below). Cerebral tissue of both male and female pups were
utilized in the study.
Coating Plates
96-well or 24-well plates were precoated with 0.01% Poly-L-Lysine (PLL) prior
to starting cell culture to give the neurons a surface to attach to in the wells. After 24
hours in an incubator, the PLL was removed and washed 3 times with HPLC-grade water.
The plates were then treated with aggrecan and/or the novel glycans at various
concentrations, as indicated on the respective figures. The plates with glycans were then
incubated at 37°C for 4 hours to allow adherence. The treatment was removed, and the
plates were washed with HPLC water three times, vacuuming off the HPLC water after
each wash.
Culturing Neurons
Pregnant Sprague Dawley rats were euthanized 17 days postcoitum with
isoflurane anesthesia followed by cervical dislocation. The ventral side of the rat was
then cleaned with ethanol. The embryos were removed and placed into a 10 cm dish on
ice with Hank’s Balanced Salt Solution (HBSS). To extract the neurons, a midsagittal
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incision was made down the brain and transversely across the occipital bone. After
extracting the brain from the embryos, the hemispheres were separated, the meninges
were removed, and then placed into 15mL conical with 1X HBSS. HBSS was then
removed and added Papain/HBSS solution for 20-25 minutes in the incubator to
enzymatically digest the tissue. After incubation, Papain/HBSS solution was removed.
The neurons were washed with pre-warmed Neurobasal media, 45 mL FBS, LGlutamine, and 5 mL pen strep three times before being titurated with media using a
glass pipette. The supernatant was run through the filter and remaining brains were
titurated two more times. The neurons were plated with a cell density of 250,000
cells/cm2 in each pre-treated well, then incubated at 37°C in the presence of 5.0% CO2
for 24 hours. After 24 hours, the media was replaced with new neurobasal media with
B27 supplement, L-Glutamate, and 5 mL pen strep and continued to incubate for another
24 hours (Ashpole, 2011). After culturing neurons on the pre-treated plates, they were
placed in an incubator at 37°C and 5% CO2 for 48 hours.
Immunostaining Cells
Forty-eight hours after incubation, cells were fixed with 4% paraformaldehyde
(PFA) in phosphate buffer for 20 minutes and permeabilized with 0.1% Triton X-100 in
PBS for 20 minutes. Then, cells were blocked with 0.1% Triton X-100 in PBS with 5%
bovine serum albumin (BSA) for 1 hour, immunostained with anti-β-Tubulin antibody
(Cell Signaling Technology, Rabbit mAb, 2128S, 1:100) in PBS overnight at 4°C.
Following removal of the primary antibody, the wells were washed 3 times with PBS for
5 minutes and treated for 1 hour in the dark with a 488 nm fluorescent goat anti-rabbit
(ThermoFisher, 1:1000). Plates were then rinsed three times with PBS for 5 minutes and
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treated for thirty minutes in the dark with DAPI (ThermoFisher, EN62248, 1:1000).
Plates were again rinsed three times with PBS for 5 minutes and stored in PBS.
MTS Assay
CellTiter 96Ò AQueous One Solution Reagant was used to perform the MTS to
determine the viability of the cells left on the plate following treatment. Active cells will
metabolize the reagent and change it to formazan, thus changing the color form a pale
yellow to a dark purple, allowing detecting of viable cells with visible light. The reagent
includes tetrazolum, as well as electron coupling reagents to reduce the reagent to
eventually form the indicative formazan (Riss, et al., 2013). After the CellTiter 96Ò
AQueous One Solution Reagant was added to the wells, the plates were placed in the
incubator for 1-2 hours once an obvious color change from pale yellow to dark purple
was observed. The plate was then placed in a plate reader and read at an absorbance of
490 nm.
Gene Expression
A subset of cells was grown for seven days to examine long-term changes in
structure and gene expression. These cells were cultured on 6cm round dishes until RNA
was isolated using the RNeasy kit. For this, 350 µl of Buffer RLT was added per dish.
Plates were scraped and the cells and Buffer RLT were pipetted in spin columns. Samples
were centrifuged for 15 seconds at 8000 x g and flow through was discarded. 700 µl of
Buffer RW1 was added and centrifuged for 15 seconds at 8000 x g, then flow through
was discarded. Then, 500 µl of Buffer RPE was added to the spin columns and
centrifuged at 8000 x g for 15 seconds. This step was repeated, but the samples were
centrifuged for 2 minutes instead. Flow through was discarded between each step.
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Samples were then centrifuged again at full speed for 1 minute to dry the membranes.
Following this, approximately 50 µl of RNase-free water was added to the spin column,
and samples were spun in the centrifuge at 8000 x g for 1 minute to remove the RNA
from the column. Nanodrop RNA was used to identify concentration and purity of
samples. Then, Applied Biosystems High Capacity RNA-to-cDNA Kit was used to
convert RNA samples to cDNA, and TaqMan Universal PCR Master Mix and TaqMan
gene specific primers (PTPRS, PTPRF, RTN4R, RTN4RL1, RTN4RL2) were used to run
a real-time PCR and was ran for 40 cycles.
Imaging
Following staining, multi-well plates were imaged on a High Content Analysis
Nikon Ti2-E Microscope with CSI S Plan Fluor ELWD 20x Ph1 ADM objective with
DAPI (395 nm) and FITC (470 nm) fluorescent filters, or with Plan Apo l 60x Oil
objective with DAPI (395 nm), FITC (470 nm), and TRITC (532 nm) fluorescent filters
with 200 ms exposure. Image locations were selected at random.
Image Analysis
All data was saved and exported using Excel (Microsoft Office, 2016). Sholl
Analysis was used to trace neurites and count number of neurite crossings (Figure 2).
Concentric ring distance was then used to generate a curve and calculate the area under
the curve as a representation of total neurite outgrowth (ImageJ).
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Tracing

Concentric Rings

Analysis:

Figure 2: Representative image of steps of Sholl analysis to assess total neurite
outgrowth as stated above. ImageJ was used to trace all processes of neuron, with
primary process in green and additional processes in purple. Concentric ring distance was
then used to assess total crosses over a certain distance, followed by various calculations
and area under the curve analysis.
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Nikon Elements Analysis software object count was used to measure the total
percent area of green fluorescence (neurites) and normalized it to blue fluorescence
(nuclei) to confirm the total neurite outgrowth (NIS Elements AR Analysis, Version
5.02). SigmaPlot was used to create all graphs and run statistical analysis (Systat
Software, San Jose, CA). In the graphs, error bars were used to represent plus/minus
standard error measurement (± SEM) in cases where data was averaged.
Statistical Analysis
The data was evaluated by one-way analysis of variance (ANOVA) using
multiple groups. A Dunnett’s post hoc test using SigmaPlot was also used to verify
statistical significance of groups in comparison with the control (Systat Software, San
Jose, CA). All data was normalized to the control in SigmaPlot. Curve fitting was done
using a 4-parameter logistic sigmoidal curve. Results were considered statistically
significant if p < 0.05.
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III. Results
Neuron cultures were established from rat cortices and grew cell in vitro for two
days following treatment of plates for 48 hours with varying concentrations of aggrecan.
After developing neurons in culture, the neurons were fixed with paraformaldehyde and
stained using immunocytochemistry techniques and then imaged. Total neurite growth
was assessed using various methods of analysis to confirm aggrecan inhibits neuronal
growth at increasing concentrations, as previously demonstrated in other publications
(Johnson, 2002). Sholl analysis was used to determine what concentration of aggrecan
statistically significantly inhibits neuronal growth (Figure 3C). Because each row of the
24-well plate was treated with a different concentration of aggrecan, the graph represents
the average area of neuron processes per nuclei. All data was normalized to the control.
As the concentration of aggrecan increased, there was a significant decrease in neurite
outgrowth at 5.0, 7.5 and 10.0 micrograms/milliliter of aggrecan. Further analysis of total
neurite growth following with increasing concentrations of aggrecan was assessed using
area of neurite coverage and longest neurite quantification, and the results indicated that
7.5 and 10.0 micrograms/milliliter of aggrecan significantly inhibited neurite outgrowth
(Figure 3D-E). From this, it was determined that 10 micrograms/milliliter of aggrecan
would be used as a standard concentration of aggrecan in this experiment. All other
treatments with aggrecan therefore have a concentration of 10 micrograms/milliliter
unless stated otherwise.
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Figure 3: Increasing concentration of aggrecan exhibited neurite outgrowth inhibition,
while known glycans do not inhibit neurite outgrowth. (a) cortical neuron cells were
cultured at 250,000 cells/cm2 and treated with 10 µg/mL aggrecan. Neurons were fixed
and stained with b-tubulin (green) and DAPI (blue). Scale bar represents 50 µm. (b)
cortical neurons treated with water for control, scale bar represents 50 µm. (c) Sholl
analysis of neurons treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan.
*, p <0.05, n=12 (d) area analysis of cortical neurons treated with water, 5 µg/mL, 7.5
µg/mL, and 10 µg/mL of aggrecan. *, p <0.05, n=12 (e) neurite length of cortical neurons
treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan. *, p <0.05, n=12
Representative images of cortical neurons treated with chondroitin (f), chondroitinase (g),
and heparin (h). Scale bars represent 50 µm. (i) cell count normalized to control of known
glycans chondroitin, chondroitinase, enoxaparin, and heparin. n=8-16 (j) MTS
absorbance assay of known glycans to test for toxicity, n=8 (k) area analysis of known
glycans normalized to control, n=8-16
15

In comparison to aggrecan’s inhibitory effect on neurite outgrowth, cortical
neurons treated with 10 micrograms/milliliter of known glycans alone revealed that these
glycans do not inhibit neurite outgrowth, nor did these glycans decrease number of nuclei
(Figure 3I, K). An MTS absorbance assay was also conducted on cells treated with these
glycans to further to assess viability, and results support that these glycans had no
toxicity effects on the neurons (Figure 3J).
Novel sulfated glycans from marine life were then applied to the culture plates
(10 micrograms/milliliter) prior to the addition of cortical neurons. These novel glycans
and derivatives were provided by Dr. Vitor Pomin. Forty-eight hours after plating
neurons were analyzed by cell count, area analysis, and for neuronal viability to confirm
that novel glycans alone did not contribute to toxicity for neurons (Figure 4G, H, I).
Results showed that novel glycans did not significantly alter number of nuclei, nor did
they contribute to toxicity. LVP2HD did, however, show an increase in metabolic activity
compared to other glycans (Figure 4H). Additionally, novel glycans did not exhibit a
decrease in total processes following area analysis, and treatment of ELHD, LVP1HD,
and LVP2HD alone, without the presence of inhibitory molecules showed a significant
increase in total processes per cell (Figure 4I). Structures of novel glycans are exhibited,
with R in E. lucunter representing at sulfated group in EL, and is 60% sulfated in ELHD.
R in LVP2 represents a sulfate group, while being 80% sulfated in LVP2HD (Figure 4A,
B, C). Sulfation patterns for LVP1HD exhibit undefined selective sulfation.
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Figure 4: Novel sulfated glycans do not inhibit neurite outgrowth. (a) structure of agalactose 2 sulfate glycan from E. lucunter, R=60% OSO3- and 40% H for ELHD. (b)
structure of novel glycan from LVP1 (c) structure of 3-linked 4-sulfated a-fucan glycan
from LVP2, R=80% OSO3- and 20% H for LVP2HD. Representative images of cortical
neurons treated with 10 µg/mL of E.L (d), LVP1HD (e), and LVP2HD (f). Scale bars
represent 50 µm. (g) nuclei count of cortical neurons treated with 10 µg/mL of novel
glycans, n=8 (h) MTS absorbance assay of cortical neurons treated with 10 µg/mL of
novel glycans, *, p<0.05, n=8 (i) area analysis of cortical neurons treated with 10 µg/mL
of novel glycans, *, p<0.05, n=8
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Next, the protective ability of various novel glycans were tested against 10
micrograms/milliliter of aggrecan at the same concentration used in Figure 4 to
demonstrate the ability of novel sugars to outcompete aggrecan. Images were analyzed
using sholl analysis and nuclei count. After completing sholl analysis, the number of
neurite crossings from the soma were plotted, then the area under each curve was
integrated and calculated to generate a bar graph. For these sets of data, an ANOVA
statistical analysis was run with a Dunnett’s post hoc test to determine which glycans
significantly outcompeted aggrecan’s inhibitory influence on the neuron culture. Again,
all data was normalized to control and error bars representing ± SEM. Sholl analysis
revealed that EL, ELHD, LVP1HD, LVP2, and LVP2HD, statistically outcompeted
aggrecan and allowed for neurite growth (Figure 5E). Additionally, nuclei count of
neurons treated with both novel glycans and aggrecan was conducted (Figure 5F). From
this, it was determined that LVP1HD and LVP2HD allowed for an increase in nuclei
count as well.
Following this, it was hypothesized that these novel glycans allow for neurite
outgrowth in a concentration dependent manner (Snow, 1992). Before beginning
concentration response curves with the novel glycans, potency of chondroitin on neuronal
growth was tested, as it has been previously published in literature that chondroitin
allows for growth in a concentration-dependent manner. Various concentrations of
chondroitin were applied to neurons and viability was assessed using area analysis
(Figure 6E).
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Figure 5: Novel glycans outcompete aggrecan. Representative images of cortical neurons
treated with 10 µg/mL aggrecan (a), 10 µg/mL aggrecan + 10 µg/mL ELHD (b), 10
µg/mL aggrecan + 10 µg/mL LVP1HD (c), and 10 µg/mL aggrecan + 10 µg/mL
LVP2HD (d). Scale bars represent 50 µm. (e) area under the curve from sholl analysis of
cortical neurons treated with 10 µg/mL aggrecan + 10 µg/mL novel glycans; *, p< 0.05,
**, p>0.001, n=12 (f) nuclei count of cortical neurons treated with 10 µg/mL aggrecan +
10 µg/mL novel glycans; *, p<0.05, n=6
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Concentrations of 0.15625 to 20.0 micrograms/milliliter of chondroitin was
applied and data was assessed again using a one-way ANOVA with Dunnett’s post hoc
test vs control. All data was normalized to control. From this assay, it was determined
that concentrations exceeding 2.5 (5.0, 10.0 and 20.0) micrograms/milliliter of
chondroitin were significant concentrations that allowing for neurite outgrowth and
arborization. The potency of chondroitin in the presence of 10 micrograms/milliliter of
aggrecan was then assessed (Figure 6F). Concentrations of 0.15625-20.0
micrograms/milliliter of chondroitin was applied with 10 micrograms/milliliter of
aggrecan. Data was normalized to the control and was tested for significance with a oneway ANOVA with a Dunnett’s post hoc test. Similar to when chondroitin was tested
without aggrecan, chondroitin concentrations of 5.0, 10.0, and 20.0
micrograms/milliliters significantly increased neurite growth by outcompeting 10.0
micrograms/milliliters of aggrecan, with 20 micrograms/milliliter of chondroitin having a
p value <0.001.
After determining from the sholl analysis that LVP2 significantly impacted total
neurite outgrowth, LVP2 became our key glycans of interest and was further studied later
with concentration-response curves. Similar to the chondroitin, LVP2 alone was applied
at various concentrations to neurons, and viability was assessed using a one-way
ANOVA with a Dunnett’s post hoc test (Figure 6H).
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Figure 6: Concentration dependent response of chondroitin and LVP2 on cortical neurite
outgrowth. Representative images of cortical neurons treated with water for control (a), 5
µg/mL chondroitin (b), 10 µg/mL chondroitin (c), and 20 µg/mL chondroitin (d). Scale
bars represent 100 µm. (e) area analysis of chondroitin concentration curve, *, p <0.05,
n=8 (f) area analysis of chondroitin + 10 µg/mL aggrecan concentration curve, *, p
<0.05, **, p<0.001, n=8 (g) area analysis of LVP2 + 10 µg/mL aggrecan concentration
curve, *, p <0.05, **, p<0.001, n=8 (h) nuclei count of LVP2 + 10 µg/mL aggrecan
concentration curve, *, p <0.05, **, p<0.001, n=8
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It was determined that 2.5 and 5.0 milligrams/milliliter of LVP2 significantly
increased the number of nuclei, with a p value of <0.05, while 10.0 and 20.0
milligrams/milliliter of LVP2 significantly increased the number of nuclei as well with a
p value of <0.001. The same concentrations of LVP2 were again applied to cortical
neurons, but with the presence of 10.0 micrograms/milliliter of aggrecan (Figure 6G).
Again, data was assessed with area analysis and statistical analysis was conducted with a
one-way ANOVA with Dunnett’s post hoc test. Concentrations of 1.25, 2.5, 5.0, and 10.0
micrograms/milliliter of LVP2 significantly outcompeted aggrecan to allow for neurite
outgrowth. However, 20.0 micrograms/milliliter exhibited a decrease in total processes.
Because of the protective ability the novel glycans exhibited for neurite growth in
the presence of aggrecan, the impact of glycans and aggrecan on size and shape of growth
cones was tested (Figure 7). It was hypothesized that increases growth cone size might
have implications for permissive growth environment.
Cortical neurons were treated with increasing concentrations of aggrecan, stained
and imaged to view growth cones (Figure 7D). Growth cone size was assessed using
ROI analysis. Following this, it was determined that increasing concentrations of
aggrecan exhibited decreased size in growth cones, and 10.0 micrograms/milliliter of
aggrecan exhibited significant decrease of growth cone size. Following this, it became
clear that decreased neurite outgrowth is correlated with decreased growth cone size.
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Figure 7: Analysis of growth cones on cortical neurons treated with aggrecan and novel
glycans. Representative images of growth cones on cortical neurons treated with water
(a), 10 µg/mL aggrecan (b) and 10 µg/mL aggrecan + 10 µg/mL LVP1HD. Scale bars
represent 10 µm, neurons were fixed and stained with b-tubulin (green), DAPI (blue),
and phalloidin (red). (d) growth cone area analysis done by ROI analysis of cortical
neurons treated with water, 5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan. *, p <0.05,
n=24 (e) growth cone area analysis done by ROI analysis of cortical neurons treated with
10 µg/mL aggrecan + 10 µg/mL glycans, *, p <0.05, n=8
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Assessment of growth cone size of glycans in the presence of 10.0
micrograms/milliliter of aggrecan was then conducted to determine if glycans
outcompeted aggrecan to an extent that exhibited significant increase in growth cone size
(Figure 7E). Analysis was conducted using a one-way ANOVA was a Dunnett’s post
hoc test, and all glycans tested, except for ELHD, showed significant increases in growth
cone size compared to neurons treated solely with aggrecan.
Additional analysis of neurons treated with aggrecan for one week, instead of 48
hours, was conducted to assess if aggrecan continued to exhibit its inhibitory effects of
total neurite outgrowth in a long-term effect (Figure 8A). After conducting a one-way
ANOVA, it was found that 5.0, 7.5, and 10.0 micrograms/milliliter of aggrecan exhibited
a significant decrease in neurite outgrowth even one week after plating, thus supporting
that the effects of aggrecan on neurite outgrowth are both immediate and long-term.
The mRNA expression of pathways that allow for neurite outgrowth was assessed
using qPCR. Specifically, expression of PTPRS, PTPRF, RTN4R, RTN4RL1, and
RTN4RL2 was examined in 7-day old neurons to possible determine what mechanism
lies behind the glycans that provide the best potential for neurite growth, plasticity, and
differentiation. Gene expression fold change was normalized to GAPDH for comparison
of gene expression levels, and neurons were assessed in comparison to either water for
control, chondroitin, and LVP2HD (Figure 9).
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Figure 8: 7-day growth analysis (a) area analysis of cortical neurons treated with water,
5 µg/mL, 7.5 µg/mL, and 10 µg/mL of aggrecan for one week. *, p <0.05, n=8
Representative images of cortical neurons treated with water (b) and 10 µg/mL of
aggrecan (c) for one week. Scale bar represents 50 µm.
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Figure 9: Gene expression fold change normalized to GAPDH on water, chondroitin, and
LVP2HD in the absence of aggrecan; n=5
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Chondroitin was utilized for comparison in gene expressed due to copious
amounts of previous literature confirming our findings of its growth permitting
properties. LVP2HD had proven to provide the greatest growth permission of all glycans
testing, making it the reason why it was also a candidate for gene analysis.
PTPRS and PTPRF are genes that regulate a variety of cellular processes such as
cell growth, differentiation, cell-to-cell interaction, axon generation, and axon guidance
(Shen, 2009). Nogo 66 receptors such as RTN4R, RTN4RL1, and RTN4RL2 are
responsible for encoding the receptor that medicates axonal regeneration and plasticity in
the CNS (Fournier, 2001). Data was normalized to control and following analysis it was
determined that there was no difference in PTPRS, PTPRF, RTN4R, RTN4RL1, and
RTN4RL2 between control, chondroitin, and LVP2HD.
In addition to the novel glycans from the marine organisms, a preliminary study to
examine the effect of chondroitin sulfates with varying lengths on neurite outgrowth was
conducted. The goal was to determine if oligosaccharides [n] residues in length would
have an impact on neurite outgrowth, or if there was a correlation in length and neurite
outgrowth. These glycans were provided by Dr. Joshua Sharp’s laboratory.
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Figure 10: Chondroitin sulfates at varying [n]’s weight analysis. Representative images
of cortical neurons treated with water for control (a), 10 µg/mL aggrecan (b), and 10
µg/mL DP4 (992 g/mol) chondroitin (c). Scale bars represent 100 µm. (d) area analysis of
chondroitin sulfates with varying lengths impact on cortical neurite outgrowth alone,
n=8-16 (e) area analysis of chondroitin sulfates with varying lengths impact on cortical
neurite outgrowth in presence of 10 µg/mL aggrecan, *, p <0.05, n=8-16 (f) MTS
absorbance assay for toxicity assay on 10 µg/mL chondroitin sulfates with varying
lengths, n=8-16
28

Partially depolymerized chondroitin sulfates from 503 g/mol to 3472 g/mol, as
well as full length CS and KS were applied to cortical neurons without the presence of
aggrecan, and total neurite outgrowth was assessed using area analysis with one-way
ANOVA and Dunnett’s post hoc versus control (Figure 10D). One-way ANOVA failed
amongst all groups and showed no significant impact on neurite outgrowth. Area analysis
was conducted on cut chondroitin sulfates in the presence of aggrecan, with a one-way
ANOVA with Dunnett’s post hoc test versus aggrecan for control (Figure 10E).
Following analysis, full length CS and 992g/mol partially depolymerized chondroitin
sulfate exhibited significant increases in total neurite outgrowth in the presence of
aggrecan.
An MTS absorbance assay was also conducted on the partially depolymerized
chondroitin sulfate to confirm that none of the samples showed toxicity to neuronal
outgrowth (Figure 10F). A one-way ANOVA with a Dunnett’s post hoc test versus
control exhibited no differences on groups, thus demonstrating that no samples were
toxic.
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IV. Discussion
The data show that several novel sulfated glycans provided rescuing effects on
neurite outgrowth in vitro against aggrecan. Additionally, the novel glycans exhibited
increasing neurite outgrowth in a concentration dependent manner. The overall increase
in axonal growth in the presence of both aggrecan and novel glycans suggest that the
glycans allow the environment to be growth permissive, indicating that the glycans may
provide a potential window for plasticity following the upregulation of KS/CSPGs with
injury. Data from chondroitin sulfates with varying [n] residues indicate that size of
glycan and neurite outgrowth are not related.
In accordance with the growth cone data, increasing concentrations of aggrecan
lead to smaller growth cones, while nearly all neuron cultures treated with aggrecan and
novel glycans exhibited a significant increase in growth cone size and shape. Previous
studies have confirmed that CS/KSPGs stop or stall the development of growth cones and
act as a barrier to growth cone advances (Snow et al., 1990, Wu et al., 1992). This growth
inhibitory mechanism may be indicative of neuronal regeneration (Hynds, 1999). It has
also been previously discussed that the regulation of growth cones through CSPGs may
be dependent on the structure and conformation of the CSPG, and that CSPGs may affect
growth cones by possibly binding directly to the growth cone (Snow, 1996) Surprisingly,
qPCR data revealed no change in expression of PTPRS, PTPRF, RTN4R, RTN4RL1, and
RTN4RL2. PTPRS and PTPRF are leukocyte common antigen-related (LAR) subfamily
of receptors that modulate neuronal development and axonal regeneration (Uetani, 2006).
PTPRS is a major CSPG receptor in sympathetic neurons, and previous research has
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revealed that the absence of PTPRS restores axon outgrowth (Gardner, 2013). The results
depicting no change in PTPRS expression when treated with novel glycans indicate that
the novel glycans do not affect neurite outgrowth by alterative of PTPRS receptors.
Furthermore, the results demonstrating the absence of change in expression of PTPRF
indicate that the novel glycans do not alter neurite outgrowth by interaction of the LAR
receptors. Previous research has indicated that CSPGs bind to Nogo receptors (RTN4R,
RTN4RL1, RTN4RL2) for myelin associated growth inhibition (Sharma, 2012). Overall,
the expression of these genes was not altered at day 7 in vitro; however, it is possible that
these genes were alters in the first day or two of culture and set the cascade. In order to
further explore this, the expression of these genes and proteins should be quantified
throughout the growth periods of culture. Additionally, changes in the function of the
receptors may need to be tested in order to provide insight on the mechanism of action for
these novel glycans to allow for neurite outgrowth.
Previous research regarding CSPGs as neurite outgrowth modulators indicate that
Nogo receptors are novel receptors for CSPGs, which may provide an insight into the
mechanism of CSPG inhibition (Dickendesher, 2012). Therefore, it is understandable that
CSPG inhibition may not be due to decreases in Nogo receptor expression, but due to the
binding of CSPGs to the receptors itself. PTPRS, another previously identified CSPG
receptor, plays a role in converting growth cones into a dystrophic state by tightly
binding them with CSPG substrates, thus bringing a deeper understanding of the role of
PTPRS in the mediation of growth of neurons (Lang, 2015). With the possibility of
PTPRS being a possible therapeutic in relieving CSPG-mediated inhibition, our data
demonstrates that the expression of the genes are not impacted by CSPGs, but rather
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perhaps the mechanism by which CSPGs interact with PTPRS and other genes may be
affected.
Limitations of Experiment
Because this study was only conducted in vitro, it is unknown if these novel
glycans can continue to exhibit its neuroprotective properties in the living system. It is
important to conduct in vivo testing in order to determine possible side effects and the
total effects the treatment may have on human health. With this in mind, an in vivo test
with induced glial scarring following injury may provide monumental data and
information regarding glycans influence on breaking down the CS/KSPG barrier formed
following TBI or SCI. Additionally, this study could have also been done in vitro with
astrocytes present to help recapitulate more of the cellular dynamics one would expect to
see if the astrocytes would respond to the glycans and thereby alter neurons indirectly.
Many of the treatments changed in cell number, so changes in neurite size could
be confounded by the cell-number. The number of cells that was plated on the first day
remained the same in each well. The differences in cell number are likely attributed to
survival upon plating. However, when performing calculations and data analysis, data
was normalized to total nuclei coverage to allow distinct separation between cell number
and neurite outgrowth. This method of analysis reduces confounding variables, however
we cannot rule out that differences in growth may be influenced by changes in cell
density, as neurons frequently display contact inhibition.
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Future Directions
Further directions include investigation of novel glycan structure, to perhaps
understand the mechanism behind the interaction of novel sulfated glycans and neurite
outgrowth. Since sulfation patterns directly influence conformation and dynamics,
continuing to elucidate sulfation pattern structure-function in novel glycans may be
important in understanding ECM interactions. Addressing the variation in novel glycan
sulfation patterns, size, dynamics, and conformation by utilizing liquid-state nuclear
magnetic resonance (NMR), spectroscopy, scalar coupling constant, nuclear overhauser
effect (NOE) profiles, and other models of analysis to explore the dynamics of molecular
interactions in neurite regeneration. Investigation of a combination of differentiating
sulfation patterns and neurite growth promoting abilities of novel glycans can allow for
further investigation of the structure of those that rescued structure the most in response
to neurite growth inhibition due to CS/KSPGs.
In vivo testing will provide further insight into possible biomedical functions of
the novel sulfated glycans, and may help determine what glycan provides the best
potential for neurite growth, plasticity, and differentiation. Further analysis of growth
cone shape and size may provide further insight on the mechanism of the interaction of
novel glycans with neurite outgrowth. Filopodia projections have been linked to dendrite
creation when new synapses are formed in the brain, while lamellipodia seem designed
for persistent protrusion over a surface.
Analysis of changes of dendritic spines may provide further insight into the
plasticity of neurite outgrowth and the mechanism by which novel glycans may allow for
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neurite outgrowth. Dendritic spines are considered as excitatory postsynaptic sites that
express high levels of plasticity, and morphology of spines correlate with the level of
plasticity (De Vivo, 2013).
The size and shape of spines correlate with calcium kinetics in the spines, which
may be significant for regulating the communication between synapses (Hering, 2002).
Specifically, filopodial protrusions indicate novel excitatory synapses, and filopodial
protrusions become increasingly sparse as maturation furthers (De Vivo, 2013).
Meanwhile, the shorter spine necks of mushroom and stubby spines may also be of
importance. Therefore, classification of spines based on size by cup shape, mushroom,
stubby, thin, and filopodium, as well as calcium signaling, may provide further insight
into the mechanism behind the novel glycans’ impact on neurite outgrowth.
Previous studies have demonstrated that CSPGs restrain motility of dendritic
spines, and that degradation of CSPGs allow for the potentiation of existing synapses (De
Vivo, 2013). With this in mind, we hypothesize that analysis of dendritic spines of
neurite treated with CSPGs such as aggrecan and novel glycans will ultimately lead to
potentiation of synapses and increased motility of dendritic spines.
Overall Conclusions
Sulfated glycans, both from marine life and other sources, possess significant
potential to outcompete the growth inhibitory CS/KSPG barrier. The exact molecular
mechanism by which these glycans exert their neurostimulatory effects is unknown, but
further studies of glycan structure and sulfation may provide more insight into the
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mechanism. Results may tentatively provide an insight on the mechanism of neurite
inhibition and regeneration, as well as cell-to-cell communication in the central nervous
system. This may open the opportunity for a greater understanding of proteoglycans as
critical regulators of cell structure in plants and animals, and may allow for further
studies aimed at developing pharmacological agents that may treat spinal cord or brain
injuries.
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